$IMRX News
Last published 2d ago
- 2d agoIMRXImmuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of DirectorsGlobeNewswire- Former TESARO Chief Commercial Officer and Nuvalent board member brings extensive experience in oncology product launches and commercial strategy - - Led commercialization of ZEJULA for ovarian cancer at TESARO and
- 2d agoIMRXImmuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of DirectorsGlobeNewswire
- 5d agoIMRXAtebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026GlobeNewswire- Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth...
- 5d agoIMRXAtebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026GlobeNewswire- Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival extended by
- 1w agoIMRXImmuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation ConferenceGlobeNewswireNEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that
- 1w agoIMRXImmuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR SymposiumGlobeNewswire- Atebimetinib in combination with chemotherapy has shown excellent results in Phase 2 clinical trials, including 17.3 months median overall survival in first-line pancreatic cancer patients treated with atebimetinib +
- 1w agoIMRXImmuneering Corp - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoIMRXImmuneering Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire- Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in the first half of
- 2w agoIMRXImmuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026GlobeNewswire- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer - -MAPKeeper 301 builds on
- 2mo agoIMRXImmuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended SurvivalGlobeNewswire- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months - - New analyses evaluate the overall survival
- 2mo agoIMRXImmuneering to Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that
- 2mo agoIMRXImmuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line PatientsGlobeNewswire- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s
- 3mo agoIMRXImmuneering Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1 - - Phase 3
- 3mo agoIMRXPublication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic InhibitionGlobeNewswire- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK
- 3mo agoIMRXImmuneering Corporation Announces Grants of Inducement AwardsGlobeNewswireNEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously announced on June
- 4mo agoKLRSPEPGIMRXKalaris Appoints Laurie Keating to Board of DirectorsGlobeNewswireBERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ:KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
- 4mo agoIMRXImmuneering Appoints Andrew Gengos as Chief Financial OfficerGlobeNewswire- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering
- 5mo agoIMRXImmuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic CancerGlobeNewswireGlobal pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endpoint of overall
- 5mo agoIMRXImmuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCOGlobeNewswire- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treatment-related
- 5mo agoIMRXImmuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus ChemotherapyGlobeNewswire- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade 3 or higher
- 6mo agoIMRXImmuneering Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - - Pivotal Phase 3 MAPKeeper
- 6mo agoIMRXImmuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual MeetingGlobeNewswire- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO presentation will highlight
- 6mo agoIMRXImmuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and BeyondGlobeNewswireAnalysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors rarely acquire the
- 7mo agoIMRXImmuneering to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireNEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that Ben
- 8mo agoIMRXImmuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswire- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track
- 8mo agoIMRXImmuneering to Present at the Leerink Global Healthcare ConferenceGlobeNewswireNEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that
- 8mo agoIMRXImmuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireNEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that
- 10mo agoIMRXImmuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnPGlobeNewswire- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates
- 10mo agoIMRXImmuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026GlobeNewswireNEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will
- 10mo agoIMRXImmuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMAGlobeNewswire– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Overall survival
- 11mo agoIMRXNBIImmuneering to be Added to the Nasdaq Biotechnology Index (NBI)GlobeNewswireNEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is
- 11mo agoONCYIMRXTNGXMRNA+1Pancreatic Cancer Survival Gains Accelerate as Novel Therapies AdvancePR NewswireUSANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immune system to attack pancreatic tumors by...
- 11mo agoIMRXImmuneering to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireNEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management
- 11mo agoALXOERASIMRXONCY+1Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106BGlobeNewswirePALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and platform immunotherapies
- 12mo agoIMRXImmuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical UpdatesGlobeNewswire- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private placement with
- 1y agoIMRXImmuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025GlobeNewswire- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday, November 12, 2025, at
- 1y agoIMRXImmuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025GlobeNewswireNEW YORK, Sept.
- 1y agoIMRXImmuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to SanofiGlobeNewswireNEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public
- 1y agoIMRXImmuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to SanofiGlobeNewswireNEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten public offering of
- 1y agoIMRXImmuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnPGlobeNewswire- 86% overall survival (OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects regulatory
- 1y agoIMRXImmuneering Appoints Dr. Thomas Schall as Chairman of the BoardGlobeNewswireNEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall,
- 1y agoIMRXImmuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25GlobeNewswire- Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company will present a
- 1y agoIMRXImmuneering Announces Closing of $25 Million Private PlacementGlobeNewswireCAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the closing of its previously
- 1y agoIMRXLLYImmuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with OlomorasibGlobeNewswire- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering
- 1y agoIMRXImmuneering Announces $25 Million Private PlacementGlobeNewswireCAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a
- 1y agoIMRXImmuneering Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswire- Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% overall survival
- 1y agoONCYKZIAIMRXNUVB+1Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step UpPR NewswireUSA News Group News Commentary – Cancer rates are rising everywhere, but more dramatically in some places. According to a new analysis of CDC data,...
- 1y agoONCYIMRXGRALINTS+1With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in OncologyPR NewswireUSA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor ...
- 1y agoIMRXImmuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer PatientsGlobeNewswire- 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached - - Striking tumor reductions with 39%
- 1y agoIMRXImmuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025GlobeNewswireCAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a